FDA approves Biogen's process for Tysabri production

04/17/2009 | Boston Globe (tiered subscription model), The

Biogen Idec secured FDA approval for its high-titer procedure used to produce Tysabri, a drug for treating relapsing types of multiple sclerosis and moderate-to-severe active Crohn's disease. The company now expects a fourfold increase in production, said Bob Hamm, Biogen's chief operating officer.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care